Market Overview:

The global monoclonal antibodies market size reached US$ 207.4 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 307.8 Billion by 2028, exhibiting a growth rate (CAGR) of 6.9% during 2023-2028.

Monoclonal antibodies (mAbs) are laboratory-produced proteins used to serve as substitute antibodies that can enhance, modify, restore, and mimic the attack of the immune system on unwanted cells. They are utilized for detecting and targetting cancer cells for destruction by enhancing the immune system. They are also employed to block the connection between a cancer cell and proteins that promote cell growth. In addition, they prevent the formation of proteins for enabling immune system cells to work efficiently against cancer cells. Besides this, mAbs transport the radiation treatment directly to cancer cells and minimize the effect of radiation on healthy cells.

Monoclonal Antibodies Market Trends:

At present, the growing prevalence of chronic diseases, such as cancer, heart disease, stroke, diabetes, and arthritis, represents one of the key factors driving the market. Besides this, leading manufacturers are extensively investing in research and development (R&D) activities to introduce enhanced mAb drugs for treating neurodegenerative diseases, such as Alzheimer's, Huntington's, Parkinson's, and Lewy body diseases. They are also focusing on various marketing strategies to expand their customer base, which is contributing to the growth of the market. In addition, the increasing demand for humanized mAbs to treat various antigens, such as cancer cells, immunosuppression, and immunomodulatory molecules, are offering lucrative growth opportunities to industry investors. Apart from this, there is a rise in the demand for cost-efficient biosimilar mAbs to treat cancer across the globe. This, along with the burgeoning healthcare industry, is propelling the growth of the market. Moreover, technological advancements in various genetic platforms, such as next-generation sequencing, is offering a positive market outlook. Additionally, there is an increase in the employment of advanced genetic engineering technology in mAbs production around the world. This, coupled with the rising awareness among the masses about the benefits of mAb therapy, is bolstering the market growth.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global monoclonal antibodies market report, along with forecasts at the global, regional and country level from 2023-2028. Our report has categorized the market based on production method, source, indication and end use.

Breakup by Production Method:

• In Vivo
• In Vitro
   

Breakup by Source:

• Murine
• Chimeric
• Humanized
• Human
   

Breakup by Indication:

• Cancer
• Autoimmune Diseases
• Inflammatory Diseases
• Infectious Diseases
• Others
   

Breakup by End Use:

• Hospitals
• Research Institutes
• Others
   

Breakup by Region:

• North America
  • United States
  • Canada
• Asia-Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
• Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
• Latin America
  • Brazil
  • Mexico
  • Others
• Middle East and Africa
   

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being AbbVie Inc., Amgen Inc., Biogen Inc., F. Hoffmann-La Roche AG, GSK plc, Johnson & Johnson, Merck KGaA, Novartis AG, Novo Nordisk A/S, Pfizer Inc., Sanofi S.A. and Thermo Fisher Scientific Inc.

Report Coverage:

Key Questions Answered in This Report:

• How has the global monoclonal antibodies market performed so far and how will it perform in the coming years?
• What has been the impact of COVID-19 on the global monoclonal antibodies market?
• What are the key regional markets?
• What is the breakup of the market based on the production method?
• What is the breakup of the market based on the source?
• What is the breakup of the market based on the indication?
• What is the breakup of the market based on the end use?
• What are the various stages in the value chain of the industry?
• What are the key driving factors and challenges in the industry?
• What is the structure of the global monoclonal antibodies market and who are the key players?
• What is the degree of competition in the industry?